JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2− advanced breast cancer

(2015) Guy Jerusalem et al.   CANCER TREATMENT REVIEWS

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

(2015) Ana Bosch et al.   Science Translational Medicine

Trafficking of Epidermal Growth Factor Receptor Ligands in Polarized Epithelial Cells

(2013) Bhuminder Singh et al.   Annual Review of Physiology

The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo

(2013) J.-H. Lee et al.   CLINICAL CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Suppression of cytokine signaling: The SOCS perspective

(2013) Edmond M. Linossi et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells

(2013) A. M. Walsh et al.   JOURNAL OF CELL SCIENCE

Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model

(2013) Toshi Murakami et al.   LUNG CANCER

Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non-Small Cell Lung Cancer

(2013) R. Li et al.   MOLECULAR CANCER THERAPEUTICS

SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition

(2013) Nadia J Kershaw et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Suppressor of Cytokine Signaling (SOCS) 5 Utilises Distinct Domains for Regulation of JAK1 and Interaction with the Adaptor Protein Shc-1

(2013) Edmond M. Linossi et al.   PLoS One

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

(2013) M. Red Brewer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation

(2012) Daijiro Harada et al.   CANCER SCIENCE

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer

(2012) Sarat Chandarlapaty   Cancer Discovery

Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells

(2011) Huan-Chih Chiu et al.   BIOCHEMICAL PHARMACOLOGY

The many faces of Janus kinase

(2011) Matthew M. Seavey et al.   BIOCHEMICAL PHARMACOLOGY

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480

(2011) H. Xin et al.   CANCER RESEARCH

STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis

(2011) R. B. Corcoran et al.   CANCER RESEARCH

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

(2011) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

(2011) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

EGFR-targeted therapy

(2011) Loredana Vecchione et al.   EXPERIMENTAL CELL RESEARCH

Suppressor of cytokine signaling 4 (SOCS4): Moderator of ovarian primordial follicle activation

(2011) J.M. Sutherland et al.   JOURNAL OF CELLULAR PHYSIOLOGY

JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling

(2011) L. Song et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma

(2011) B. C. McFarland et al.   MOLECULAR CANCER THERAPEUTICS

Companies hope for kinase inhibitor JAKpot

(2011) Elie Dolgin   NATURE REVIEWS DRUG DISCOVERY

Feedback regulation of EGFR signalling: decision making by early and delayed loops

(2011) Roi Avraham et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling

(2011) J. Chmielecki et al.   Science Translational Medicine

Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma

(2010) Jinesh S. Gheeya et al.   CANCER BIOLOGY & THERAPY

Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor–Activating Mutations

(2010) Matthew J. Lazzara et al.   CANCER RESEARCH

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2009) W. Wang et al.   CLINICAL CANCER RESEARCH

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel

(2008) A. Sawai et al.   CANCER RESEARCH

Endocytosis and intracellular trafficking of ErbBs

(2008) Alexander Sorkin et al.   EXPERIMENTAL CELL RESEARCH

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression

(2007) Seungchan Yang et al.   EXPERIMENTAL CELL RESEARCH